EMA Chief: ‘Safety Is Our Priority’ In Review Of COVID-19 Vaccine

Data To Be Made Available Quickly After Approval

The EMA says its experts are working “around the clock” on a recommendation for conditional marketing authorization of a COVID-19 vaccine, but that it will only OK a vaccine if it is satisfied that the evidence convincingly shows the benefits are greater than the risks.

Vaccine coronavirus covid-19 ncov 2019 virus infection research, test, analysis. Coronavirus SARS-CoV-2 treatment vaccine injection laboratory testing, immunization, prevention 3D medical illustration
The EMA is evaluating four candidate COVID-19 vaccines • Source: Shutterstock

The executive director of the European Medicines Agency has gone out of her way to distinguish the approach being taken by the agency to COVID-19 vaccine approval from that of other key world regulators.

Speaking to members of the European Parliament on 10 December, Emer Cooke said that while she didn't want to comment...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography